1617P Leucine-rich 2 glycoprotein 1 (LRG1) as potential systemic biomarker for response to neoadjuvant immune checkpoint blockade in stage III melanoma

Shizhen Chen; C.C.E. De Schrijver; H. Van Rossum; Theodora C. Linders; Lianne Hoeijmakers; M.W. Lucas; Esmée P. Hoefsmit; Irene L. M. Reijers; Petros Dimitriadis; B. van de Wiel; Karin E. de Visser; Astrid A.M. van der Veldt; Helena Eriksson; Geke A.P. Hospers; Richard A Scolyer; Karijn P.M. Suijkerbuijk; Ellen Kapiteijn; A.M. Menzies; G.V. Long; Christian U. Blank

doi:10.1016/j.annonc.2025.08.2245

Related publications

Article2025

1615P Health-related quality of life in the phase III NADINA trial: Neoadjuvant vs adjuvant checkpoint blockade in stage III melanoma

Maarten Egeler, Judith Lijnsvelt, M.W. Lucas, Victoria Atkinson, Muhammad A. Khattak, Miles C. Andrews, M. Boers-Sonderen, Geke A.P. Hospers, M.S. Carlino, Jan Willem de Groot, M. Stevense-den Boer, E. Kapiteijn, K. Suijkerbuijk, P. Rutkowski, A.M. Menzies, Shahneen Sandhu, Astrid A.M. van der Veldt, G.V. Long, C.U. Blank, Lonneke V. van de Poll‐Franse

Article2025

Abstract 731: Integrating ctDNA and FDG-PET dynamics to predict pathological response following neoadjuvant systemic therapy in stage III melanoma

Wei Yen Chan, Li Zhou, Edward C. Hsiao, Jenny Lee, Ashleigh Stewart, Russell J. Diefenbach, George Au‐Yeung, Maria Gonzalez, Andrew J. Spillane, Robyn P.M. Saw, Sydney Ch'ng, Matteo S. Carlino, Richard A Scolyer, Alexander M. Menzies, Georgina V. Long, Helen Rizos

Article2017

Predictors of responses to immune checkpoint blockade in advanced melanoma

Nicolas Jacquelot, María P. Roberti, David Enot, Sylvie Rusakiewicz, Nils Ternès, Sarah Jégou, David M. Woods, Andressa L. Sodré, Morten Hansen, Yaron Meirow, Moshe Sade-Feldman, Abhishek Burra, Serena S. Kwek, Caroline Flament, Meriem Messaoudene, Connie P.M. Duong, Lieping Chen, Byoung S. Kwon, Ana C. Anderson, Vijay K. Kuchroo, Benjamin Weide, F. Aubin, Christophe Borg, Stéphane Dalle, O. Beatrix,

Article2025

233eP Association between circulating tumour DNA and FDG-PET as biomarkers of response to neoadjuvant therapy in stage III melanoma

Wen‐Ling Chan, Li Zhou, Edward Hsiao, Jenny Lee, Ashleigh Stewart, Russell J. Diefenbach, George Au‐Yeung, M. Gonzalez, Andrew J. Spillane, R.P.M. Saw, Sydney Ch’ng, M.S. Carlino, Richard A Scolyer, A.M. Menzies, G.V. Long, Helen Rizos

Article2021

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers, Robyn P.M. Saw, Judith M. Versluis, Oscar Krijgsman, Petros Dimitriadis, Karolina Sikorska, Bart A. van de Wiel, Hanna Eriksson, Maria Gonzalez, A. Torres Acosta, Lindsay G. Grijpink-Ongering, Kerwin F. Shannon, John B.A.G. Haanen, Jonathan R. Stretch, Sydney Ch’ng, Omgo E. Nieweg, Henk Mallo, S. Adriaansz, Ron Kerkhoven, Sten Cornelissen, Annegien Broeks, ,

1617P Leucine-rich 2 glycoprotein 1 (LRG1) as potential systemic biomarker for response to neoadjuvant immune checkpoint blockade in stage III melanoma

Discussion(0)

Related publications

1615P Health-related quality of life in the phase III NADINA trial: Neoadjuvant vs adjuvant checkpoint blockade in stage III melanoma

Abstract 731: Integrating ctDNA and FDG-PET dynamics to predict pathological response following neoadjuvant systemic therapy in stage III melanoma

Predictors of responses to immune checkpoint blockade in advanced melanoma

233eP Association between circulating tumour DNA and FDG-PET as biomarkers of response to neoadjuvant therapy in stage III melanoma

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma